within the swiftly evolving industry of oncology research, precise and economical mutation screening is critical for creating targeted therapies. The KRAS companies Platform performs a pivotal job Within this landscape by providing detailed solutions for KRAS mutation profiling and Evaluation. KRAS mutations, found in somewhere around ninety five%